Diagnosis of Polycythemia Vera – Role of Erythropoietin and Molecular Testing

WHO Diagnostic Criteria

Hemoglobin Thresholds

Molecular Testing for JAK2 Mutations

Minor Criteria Supporting Diagnosis

Clinical Pitfalls

Diagnostic Pathway Summary

Diagnostic Criteria for Polycythemia Vera

Major Criteria

• The World Health Organization recommends that the diagnosis of polycythemia vera requires meeting either all 3 major criteria, or the first 2 major criteria plus the minor criterion, according to the 2016 WHO revision 3
• Elevated hemoglobin or hematocrit is a major criterion, with thresholds of hemoglobin >16.5 g/dL in men or >16.0 g/dL in women, or hematocrit >49% in men or >48% in women, or increased red cell mass >25% above mean normal predicted value 3
• Bone marrow biopsy showing characteristic features, including hypercellularity for age with trilineage growth, prominent erythroid, granulocytic, and megakaryocytic proliferation, and pleomorphic, mature megakaryocytes with differences in size, is a major criterion 3, 4
• Presence of JAK2 mutation, including JAK2 V617F or JAK2 exon 12 mutation, is a major criterion, found in >95% of polycythemia vera cases 3, 5, 6

Minor Criterion

• Subnormal serum erythropoietin level below the reference range for normal is a minor criterion, helping to differentiate polycythemia vera from secondary causes of erythrocytosis 3, 6

Diagnostic Algorithm

• The National Comprehensive Cancer Network recommends two pathways to diagnosis: all 3 major criteria are met, or the first 2 major criteria plus the minor criterion 3
• The first pathway captures >97% of cases when both hemoglobin/hematocrit elevation and JAK2 mutation are present 3, 5, 7
• The second pathway captures JAK2-negative cases or those with low mutational burden, requiring 2 criteria when JAK2 is absent to increase diagnostic specificity 3, 5, 7

Critical Considerations and Pitfalls

• Exclusion of secondary causes is mandatory, including ruling out secondary erythrocytosis from hypoxia, chronic lung disease, sleep apnea, high altitude, renal tumors, hepatocellular carcinoma, and other EPO-producing tumors 6
• Iron deficiency can confound diagnosis, with hemoglobin levels potentially being falsely lowered in iron-deficient patients, and formal diagnosis requiring demonstration of WHO criteria after iron replacement 5, 7
• JAK2-negative cases require both bone marrow biopsy showing characteristic features and low EPO level for diagnosis, with consideration of testing for JAK2 exon 12 mutations if V617F is negative 3, 6

WHO Diagnostic Criteria for Polycythemia Vera and the Role of JAK2 Exon 12 Testing

Major and Minor Diagnostic Criteria

• The WHO algorithm requires either (a) both major criteria—elevated hemoglobin/hematocrit and a JAK2 mutation—plus ≥ 1 minor criterion, or (b) the first major criterion (elevated hemoglobin/hematocrit) plus ≥ 2 minor criteria. Strong guideline recommendation. [8][9]

Hemoglobin Threshold Considerations

• In men, a hemoglobin of 16 g/dL does not satisfy the first major‑criterion threshold of ≥ 18.5 g/dL (or ≥ 17 g/dL with a sustained ≥ 2 g/dL rise). This does not automatically exclude PV; diagnosis can proceed via the alternative pathway using minor criteria. Strong guideline recommendation. 9

Role of JAK2 Exon 12 Mutation

• JAK2 exon 12 mutations are formally recognized as fulfilling the second major criterion in the WHO diagnostic framework. Strong guideline recommendation. [8][9]

Supporting Laboratory Findings (Minor Criteria)

• Low or low‑normal serum erythropoietin (EPO) is a WHO‑defined minor criterion that supports primary erythrocytosis. Strong guideline recommendation. [8][9]
• Iron deficiency can mask true erythrocytosis by lowering hemoglobin while the red‑cell mass remains elevated; therefore, iron studies (ferritin, transferrin saturation) are recommended to interpret hemoglobin values correctly. Strong guideline recommendation. 8

Bone Marrow Evaluation (Minor Criterion)

• A bone‑marrow biopsy demonstrating hypercellularity with trilineage (panmyelosis) growth satisfies a WHO minor criterion. Strong guideline recommendation. [8][9]
• When bone‑marrow hypercellularity is absent, the presence of endogenous erythroid colony formation can serve as the third WHO minor criterion. Strong guideline recommendation. [8][9]

Diagnostic Flexibility Without Hemoglobin Threshold

• Polycythemia vera can be diagnosed without meeting the hemoglobin/hematocrit threshold when a JAK2 mutation (including exon 12) is present together with sufficient WHO minor criteria (e.g., low EPO, bone‑marrow hypercellularity, endogenous erythroid colonies). Strong guideline recommendation. [8][9]

Evidence Base

• The 2007 WHO proposal and the 2008 WHO revision (published in Blood 2007 and 2009) established JAK2 exon 12 mutations as a major diagnostic criterion for PV. Strong guideline recommendation. [8][9]

Diagnostic Approach for JAK2 Exon 12‑Positive Polycythemia Vera

Requirement of Minor WHO Criteria

• In patients who harbor a JAK2 exon 12 mutation but have hemoglobin values below the standard WHO thresholds, a diagnosis of polycythemia vera is permitted only when at least two minor WHO criteria are satisfied (e.g., low serum erythropoietin, bone‑marrow hypercellularity with trilineage proliferation, or endogenous erythroid colony formation)【10】.

Confirmation After Iron Repletion

• If iron deficiency is present, the formal diagnosis of polycythemia vera should be postponed until after iron replacement therapy, allowing hemoglobin/hematocrit to reach WHO diagnostic levels and confirming true erythrocytosis【10】.

WHO 2016 Hemoglobin Thresholds for Polycythemia Vera Diagnosis in India

Hemoglobin and Hematocrit Thresholds

• The World Health Organization (WHO) 2016 diagnostic criteria specify that in the Indian population a hemoglobin level > 16.5 g/dL in men or > 16.0 g/dL in women warrants evaluation for polycythemia vera. 11 Evidence strength: strong guideline recommendation.
• According to the WHO 2016 revision, the first major diagnostic criterion is either:
  
  • Men – hemoglobin > 16.5 g/dL or hematocrit > 49%
  • Women – hemoglobin > 16.0 g/dL or hematocrit > 48% 11 Evidence strength: strong guideline recommendation.

Diagnostic Workflow Trigger

• When a patient meets the above hemoglobin/hematocrit thresholds, immediate JAK2 mutation testing (V617F and, if negative, exon 12) is mandated as the first‑line investigation. 11 Evidence strength: strong guideline recommendation.

Minor Diagnostic Criteria (Bone Marrow)

• A bone‑marrow biopsy that shows hypercellularity with trilineage growth and pleomorphic megakaryocytes fulfills a minor diagnostic criterion for polycythemia vera. 11 Evidence strength: strong guideline recommendation.

Guideline Authority and Evidence Strength

• The WHO 2016 criteria are endorsed as strong guideline recommendations by the European LeukemiaNet (ELN) and were published in Leukemia (2018). 11 Evidence strength: strong.

World Health Organization Diagnostic Criteria for Polycythemia Vera

Molecular Testing

• JAK2 V617F mutation testing is the mandatory first‑line molecular assay, detecting >90–95 % of polycythemia vera (PV) cases and serving as a major WHO diagnostic criterion. 12
• When JAK2 V617F is negative, immediate testing for JAK2 exon 12 mutations identifies an additional ~2–3 % of PV cases; together the two assays capture >97 % of patients when combined with elevated hemoglobin/hematocrit. 13, 14

Hematologic Major Criteria

• Men meet the first major WHO criterion when hemoglobin is ≥18.5 g/dL or hematocrit >49 %; women meet it when hemoglobin is ≥16.5 g/dL or hematocrit >48 %. 12
• A sustained rise of ≥2 g/dL from baseline (reaching ≥17 g/dL in men or ≥15 g/dL in women) also satisfies the major hemoglobin/hematocrit criterion. 13, 12

Serum Erythropoietin (Minor Criterion)

• A serum erythropoietin level below the laboratory reference range constitutes a WHO minor criterion for PV. 13, 14
• Low or low‑normal erythropoietin supports a primary (clonal) polycythemia, whereas an elevated level mandates evaluation for secondary causes of erythrocytosis. 15, 16, 17
• Up to 30 % of confirmed PV patients may have erythropoietin values within the normal range; therefore a normal result does not exclude the diagnosis. 17

Bone Marrow Evaluation (Minor Criterion)

• Bone marrow biopsy is indicated when JAK2 testing is negative or when the diagnosis remains equivocal after initial work‑up. 15, 16, 17
• Typical PV marrow findings—hypercellularity with panmyelosis, pleomorphic megakaryocytes forming clusters, and reduced iron stores—satisfy a WHO minor criterion and are especially valuable in JAK2‑negative cases. 15, 16, 13, 14

Diagnostic Algorithms

• WHO Pathway 1 (captures >97 % of cases): presence of both major criteria (elevated hemoglobin/hematocrit and a JAK2 mutation) plus at least one minor criterion (low erythropoietin, characteristic bone‑marrow histology, or endogenous erythroid colony formation). 14
• WHO Pathway 2 (for JAK2‑negative or low‑burden disease): elevated hemoglobin/hematocrit plus at least two minor criteria. (cited in WHO algorithm but no specific reference provided; omitted from bullet list)

Additional Considerations

• The endogenous erythroid colony (EEC) assay is a WHO minor criterion but has limited availability and requires specialized expertise. 15, 16
• Cytogenetic abnormalities are present in only 13–18 % of PV patients at diagnosis, limiting their diagnostic utility. 15, 16
• JAK2 V617F positivity alone is insufficient for a PV diagnosis because the mutation also occurs in ~50 % of essential thrombocythemia and primary myelofibrosis; full WHO criteria must be satisfied. 12

Guideline for JAK2 Mutation Testing in Iron‑Deficient Patients Suspected of Polycythemia Vera

Clinical Context: Iron Deficiency and Polycythemia Vera

• Iron deficiency is frequently present at the time of polycythemia vera (PV) diagnosis and does not preclude ordering JAK2 mutation testing. 18
• Iron deficiency can mask true hemoglobin/hematocrit elevation because depleted iron stores may falsely lower measured hemoglobin levels. [19][18]
• The WHO diagnostic framework acknowledges that hemoglobin/hematocrit thresholds may need confirmation after iron repletion, but this does not prevent JAK2 testing while the patient remains iron‑deficient. [19][18]

Indications for JAK2 Testing (First‑Line Molecular Test)

• JAK2 V617F should be the initial molecular assay in any patient with clinical suspicion for a myeloproliferative neoplasm. 20
• Elevated hemoglobin/hematocrit thresholds that trigger testing:
  
  • Men ≥ 18.5 g/dL (Hb) or > 49 % (Hct)
  • Women ≥ 16.5 g/dL (Hb) or > 48 % (Hct) 19
• Sustained hemoglobin rise: an increase of ≥2 g/dL reaching ≥17 g/dL in men or ≥15 g/dL in women. 19
• Thrombocytosis: platelet count ≥450 × 10⁹/L, especially when accompanied by other MPN features. [21][22]
• Unexplained erythrocytosis or splenomegaly (with or without additional cytopenias). 20
• Aquagenic pruritus (intense itching after water contact), a characteristic PV symptom. 23

Diagnostic Algorithm and Additional Testing

• JAK2 V617F detects >90–95 % of PV cases and serves as a major WHO diagnostic criterion; testing can be performed while the patient receives intravenous (IV) iron. 18
• If JAK2 V617F is negative, proceed to JAK2 exon 12 mutation testing, which identifies an additional 2–3 % of PV cases. 20
• Serum erythropoietin (EPO): a low or low‑normal level is a WHO minor criterion supporting primary polycythemia. 19
• Bone marrow biopsy: hypercellularity with trilineage growth (panmyelosis) and pleomorphic megakaryocytes constitutes a WHO minor criterion. [20][19]
• Iron studies (ferritin, transferrin saturation) should be obtained to document iron deficiency and guide replacement therapy. 18

WHO Diagnostic Criteria (2022 Revision)

• Major criteria (both required):
• Minor criteria (≥1 required):
  
  • Bone marrow hypercellularity with trilineage growth. [20][19]
  • Subnormal serum erythropoietin. 19
  • Endogenous erythroid colony formation in vitro. 19

Testing Considerations in the Setting of Iron Therapy

• Do not delay JAK2 mutation testing until after iron repletion; the assay is independent of iron status and can be ordered immediately when suspicion exists. 18
• Intravenous iron does not interfere with detection of JAK2 mutations, although iron repletion may raise hemoglobin and unmask the full degree of erythrocytosis, facilitating PV confirmation. 18

Practical Recommendation for Patients Receiving IV Iron

• Order JAK2 V617F testing promptly in any patient on IV iron who exhibits:
  
  • Elevated or high‑normal hemoglobin/hematocrit for age and sex, or
  • Unexplained thrombocytosis or leukocytosis. [21][22]
  • Splenomegaly or aquagenic pruritus. 23
• The result will guide subsequent diagnostic steps and does not require waiting for completion of iron therapy. 18